Filing Analysis
Caribou Biosciences reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. While directors were elected and the auditor was ratified, a proposal to expand officer exculpation in the company's certificate of incorporation was not approved.
🚩 Red Flags
- Stockholders rejected the proposal to provide officers with expanded exculpation from fiduciary duty breaches, indicating potential shareholder dissatisfaction with corporate governance or officer accountability.
📋 Key Facts
- Election of three Class II Directors (Andrew Guggenhime, David Johnson, and Nancy Whiting) was successful.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3, regarding the exculpation of officers from certain breaches of fiduciary duty, failed to pass.
- Proposal 4, allowing for the adjournment of the meeting to solicit more votes for Proposal 3, was approved, but the company ultimately decided not to adjourn.
Caribou Biosciences announced positive long-term follow-up data from two phase 1 clinical trials: the ANTLER trial for vispa-cel (anti-CD19) in B-NHL and the CaMMouflage trial for CB-011 (anti-BCMA) in multiple myeloma. The company is moving toward a pivotal phase 3 trial for vispa-cel and expects further dose expansion data for CB-011 in H2 2026.
🚩 Red Flags
- Reported two deaths related or possibly related to vispa-cel in the pivotal subgroup (N=27).
- Reported one death related to CB-011 in the dose escalation portion (N=48).
📋 Key Facts
- Vispa-cel (ANTLER trial) showed an 82% overall response rate (ORR) and 67% complete response rate in a pivotal subgroup of 27 second-line LBCL patients.
- Vispa-cel demonstrated a median progression-free survival (PFS) of 17.1 months.
- CB-011 (CaMMouflage trial) showed a 92% ORR and 83% complete response or stringent complete response rate in 12 BCMA-naïve patients.
- CB-011 achieved 91% MRD negativity in 10 of 11 evaluable patients.
- The company has aligned with the FDA on the design of the ANTLER-3 phase 3 trial, targeting ~250 patients.
- Vispa-cel safety: One vispa-cel-related death due to IEC-HS and one possibly related death due to PML in the pivotal subgroup.
- CB-011 safety: One CB-011-related death due to immune effector cell-associated hematotoxicity across 48 patients.
Caribou Biosciences announced its financial results for the first quarter ended March 31, 2026, and provided a general business update. The disclosure was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Announced financial results for the quarter ended March 31, 2026
- Provided a business update in the accompanying press release (Exhibit 99.1)
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- The filing was signed by President and CEO Rachel E. Haurwitz, Ph.D.
Caribou Biosciences announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The candidate is currently being evaluated in the ongoing CaMMouflage Phase 1 clinical trial.
📋 Key Facts
- FDA granted RMAT designation for CB-011 on March 31, 2026.
- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy product candidate.
- The designation is for the treatment of relapsed or refractory multiple myeloma (r/r MM).
- CB-011 is currently in the CaMMouflage Phase 1 clinical trial.
Caribou Biosciences announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The filing includes a press release providing a business update alongside the financial data.
📋 Key Facts
- Reported financial results for Q4 2025 and the full year ended December 31, 2025
- Filing date of March 5, 2026
- The information was furnished under Item 2.02 and is not deemed 'filed' for liability purposes
- Includes Exhibit 99.1: Press Release Issued by Caribou Biosciences, Inc. on March 5, 2026